Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.

ABSTRACT:

Background

Heterogeneity of prostate cancer (PCa) contributes to inaccurate cancer screening and diagnosis, unnecessary biopsies, and overtreatment. We intended to develop non-invasive urine tests for accurate PCa diagnosis to avoid unnecessary biopsies.

Methods

Using a machine learning program, we identified a 25-Gene Panel classifier for distinguishing PCa and benign prostate. A non-invasive test using pre-biopsy urine samples collected without digital rectal examination (DRE) was used to measure gene expression of the panel using cDNA preamplification followed by real-time qRT-PCR. The 25-Gene Panel urine test was validated in independent multi-center retrospective and prospective studies. The diagnostic performance of the test was assessed against the pathological diagno

SUBMITTER: Johnson H 

PROVIDER: S-EPMC7706045 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature